Arcellx and Kite Pharma enter CAR T-cell therapy collaboration; $225M upfront + $100M equity

Arcellx, Inc.

Collaboration and License Agreement with Kite Pharma (Gilead) for CART-ddBCMA, a CAR T therapy for myeloma.
Arcellx receives $225M upfront cash payment and $100M equity investment from Kite.
Eligible for milestones up to $635M per NextGen Product and $508M per Non-Auto Product.
Arcellx retains co-development/co-commercialization option and royalties on Licensed Products.
Deal subject to HSR review and other regulatory approvals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.